Sr.no |
Title of project |
PI Name |
Status of the Trail |
1. |
ALK28/ENZ130-PER1_A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Biosimilar Pertuzumab (ENZENE) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer. |
Dr.Vandana Singh Kushwaha |
Ongoing |
2 |
CINC280AIN01_A prospective, multicentre, Open-label, Phase IV, Interventional study to assess the safety and efficacy of Capmatinib in Indian patients with Mesenchymal-Epithelial Transition (MET) exon 14 skipping Mutation Positive Advanced Non-small cell Lung Cancer (NSCLC) |
Dr.Vandana Singh Kushwaha |
Ongoing |
3 |
C2A03266(CA-170-302) A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA- 170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3) |
Dr.Vandana Singh Kushwaha |
Ongoing |
Waghmare C M, Pawar H J, Bhalwar R, Thakur P K.Psychometric analysis of Marathi version of an updated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ‐H&N43). Indian J Cancer 2024,61(1):180-192.
Waghmare CM, Pawar HJ, Bhalwar R.Quality of Life before and after Radiotherapy in Head and Neck Squamous Cell Cancer Patients Measured Using an Updated Head- Neck Specific EORTC QLQ-H&N43 at a Rural Tertiary Cancer Care Center. South Asian J Cancer 2024;00(00):00–00 (Ahead of print)